Company Encyclopedia
View More
name
ZAI LAB
09688.HK
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company’s oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc.
1.371 T
09688.HKMarket value -Rank by Market Cap -/-

Financial Score

19/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking18/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-28.97%E
    • Profit Margin-46.83%E
    • Gross Margin54.47%B
  • Growth ScoreB
    • Revenue YoY23.98%A
    • Net Profit YoY23.74%B
    • Total Assets YoY17.79%A
    • Net Assets YoY13.99%A
  • Cash ScoreC
    • Cash Flow Margin-213.54%D
    • OCF YoY23.98%A
  • Operating ScoreC
    • Turnover0.41C
  • Debt ScoreB
    • Gearing Ratio34.43%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    UBS lists predictions for Chinese stocks with high profit growth potential for next year (Table)

    UBS released a strategy report on the Chinese market, listing Chinese stocks with high profit growth potential for next year and giving them a "Buy" rating. The list includes Hong Kong stocks and Chinese concept stocks, such as InnoCare Pharma, Kintor Pharmaceutical, Zai Lab, Akeso, ECARX Holdings, CanSinoBIO, Zhongsheng Holdings, BeiGene, Li Auto, GDS Holdings, and iQIYI

    AASTOCKS·
    US
    ZLAB
    -0.42%
    HK
    09688
    +0.25%
    SH
    688185
    -1.43%
    AASTOCKS·
    US
    ZLAB
    -0.42%
    HK
    09688
    +0.25%
    SH
    688185
    -1.43%

    Zai Lab Ltd Announces Share Options and Restricted Share Units Grants

    Zai Lab Ltd (HK:9688) announced the grant of share options and restricted share units under its 2024 Equity Incentive Plan, including 500 options for one employee and 72,100 restricted share units for 78 employees. This initiative aims to align employee incentives with company goals, though it lacks performance targets or clawback mechanisms. The current analyst rating for Zai Lab's stock is a Hold with a price target of HK$18.50. Zai Lab is a biopharmaceutical company focused on innovative medicines, with a market cap of HK$19.26B.

    Tip Ranks·
    US
    ZLAB
    -0.42%
    HK
    09688
    +0.25%
    Tip Ranks·
    US
    ZLAB
    -0.42%
    HK
    09688
    +0.25%

    Zai Lab Ltd (1ZLB) Gets a Buy from UBS

    In a report released on November 7, from UBS maintained a Buy rating on Zai Lab Ltd, with a price target of HK$33.50. The company’s shares closed last Friday at HK$17.27.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. Zai Lab Ltd has an analyst consensus of Strong Buy, with a price target consensus of €3.78.

    Tip Ranks·
    US
    ZLAB
    -0.42%
    HK
    09688
    +0.25%
    Tip Ranks·
    US
    ZLAB
    -0.42%
    HK
    09688
    +0.25%

    According to "The Big Bank," Bank of America Securities has lowered the target price for Zai Lab to 19.92 yuan, citing pressure on core product sales

    Bank of America Securities lowered the target price for Zai Lab to RMB 19.92 due to pressure on its core product sales. The report pointed out that the company's total revenue in the third quarter increased by 13% year-on-year to USD 116 million, and the net loss narrowed by 14% to USD 36 million. The full-year revenue guidance was lowered to USD 460 million, and revenue forecasts for 2025 to 2027 were reduced by 17%, 23%, and 20%, respectively. The "Neutral" rating was reaffirmed, with R&D pipeline progress meeting expectations

    AASTOCKS·
    US
    ZLAB
    -0.42%
    HK
    09688
    +0.25%
    AASTOCKS·
    US
    ZLAB
    -0.42%
    HK
    09688
    +0.25%

    Citi lowers Zai Lab's target price to $58, third-quarter revenue misses expectations

    Citi has lowered the target price for Zai Lab to $58, citing that the company's third-quarter revenue was approximately $116 million, which was 16% and 22% below expectations. Management has reduced its revenue guidance for the year from $560 million to $590 million to at least $460 million and has canceled its operating expense balance target. Total product revenue is expected to be $457 million this year, and although management has a deep understanding of the Chinese market, challenges remain. Clinical data will become a catalyst for the stock, maintaining a "Buy/High Risk" rating

    AASTOCKS·
    US
    ZLAB
    -0.42%
    HK
    09688
    +0.25%
    AASTOCKS·
    US
    ZLAB
    -0.42%
    HK
    09688
    +0.25%
    Posts
    View More

    $Beigene(ONC.US)$Zai Lab(ZLAB.US)Trump administration plans to impose strict controls on Chinese pharmaceuticals

    mp.weixin.qq.com/s/gihUP-...